Department of Gastroenterology and Gastrointestinal Surgery, Hvidovre Hospital, University of Copenhagen, Denmark; National Institute of Public Health, University of Southern Denmark, Denmark.
Department of Gastroenterology and Gastrointestinal Surgery, Hvidovre Hospital, University of Copenhagen, Denmark.
Pancreatology. 2019 Sep;19(6):828-833. doi: 10.1016/j.pan.2019.07.042. Epub 2019 Jul 30.
Use of minimally invasive techniques has reduced mortality in walled-off pancreatic necrosis (WON) but may be costly. The aim of this study was to evaluate the actual costs associated with the endoscopic management of patients with WON.
We included a retrospective cohort of WON patients treated with endoscopic, transgastric drainage and necrosectomy (ETDN) during 2013-2014. Costs were calculated for six sub-areas based on a micro-costing model. Students T-test and non-parametric analysis of variance were performed to evaluate costs in relation to disease etiology and outcome.
We included 58 patients (50% men, median age 57 years). The most common etiologies were gallstones (57%) and alcohol (19%). Nine patients (16%) died during admission. The median length of stay was 50 days (IQR 31 days). Eighteen patients (31%) needed treatment in our intensive care unit with a median length of stay of 16 days (IQR 31 days). The mean costs and standard deviation of costs (SD) per patient were: diagnostic imaging $2,431 ($2,301), laboratory tests $3,579 ($2,477), blood products $982 ($1,734), endoscopic treatment $3,794 ($1,777), medicine $5,440 ($6,656), and ward cost $41,260 ($35,854). The mean total cost was $57,486 ($46,739). Post-ERCP pancreatitis and mortality predicted higher costs.
This study sheds light on the different costs associated with endoscopic treatment of WON. As nearly three quarters of the costs are related to ward care, initiatives aimed at reducing the length of hospital stay may have a great impact on making endoscopic treatment more cost effective.
微创技术的应用降低了包裹性胰腺坏死(WON)的死亡率,但可能成本较高。本研究旨在评估内镜治疗 WON 患者相关的实际成本。
我们纳入了 2013-2014 年期间接受内镜、经胃引流和坏死组织清除术(ETDN)治疗的 WON 患者的回顾性队列。根据微观成本模型计算了六个亚区的成本。采用学生 t 检验和非参数方差分析评估疾病病因和结局与成本的关系。
我们纳入了 58 例患者(50%为男性,中位年龄 57 岁)。最常见的病因是胆石症(57%)和酒精(19%)。9 例(16%)患者在住院期间死亡。中位住院时间为 50 天(IQR 31 天)。18 例(31%)患者需要在重症监护病房治疗,中位住院时间为 16 天(IQR 31 天)。每位患者的平均费用和费用标准差(SD)为:诊断成像$2431($2301)、实验室检查$3579($2477)、血液制品$982($1734)、内镜治疗$3794($1777)、药物$5440($6656)和病房费用$41260($35854)。总平均费用为$57486($46739)。ERCP 后胰腺炎和死亡率预测费用较高。
本研究阐明了内镜治疗 WON 相关的不同成本。由于近四分之三的费用与病房护理有关,因此旨在缩短住院时间的举措可能会对使内镜治疗更具成本效益产生重大影响。